Free Call: 1800 792 676
AusIndustry Guidance and Materials
New AusIndustry Guidance Released on Software Development
February 21st, 2019AusIndustry have released two additional guidance documents particularly relevant to claimants conducting software development R&D activities: Software activities and the R&D Tax Incentive; Guide to Common Errors; This guidance has been released following earlier material from AusIndustry indicating concerns over inappropriate claims for Software Activities, and reports in the media of large software development R&D claims being found to be ineligible during review. The general principles within this new guidance remains consistent, in that claimants must demonstrate how their software is […]
AusIndustry R&D Tax Incentive Updates For 2019
January 7th, 2019Conducting R&D activities generates new knowledge that can benefit the nation’s economy. In a recent AusIndustry information bulletin, it was mentioned that one of the main aims of the R&D Tax Incentive is to encourage Australian businesses to undertake research and development that would not be conducted otherwise. This is achieved by helping to offset some of the costs of engaging in R&D. Useful information on the R&D Tax Incentive can be accessed from page 24 in the Innovation and […]
Draft Legislation Released for R&D Tax Incentive
July 3rd, 2018The Government announced on 8 May 2018 that the Research and Development Tax Incentive (R&DTI) would be reformed and that changes would apply from 1 July 2018. Draft legislation has been released regarding amendments to the R&DTI. Stakeholder feedback is encouraged and responses can be submitted until 26 July 2018. Changes to the Bill include: Increasing the R&D expenditure threshold from $100 to $150 million; Introducing a $4 million cap on annual cash refunds (the cap excludes clinical trials). Refunds over […]
R&D Tax Incentive Changes Announced in 2018-19 Budget
May 9th, 2018In response to the recommendations in the ‘2016 Review of the R&D Tax incentive’ the government has announced proposed R&D Tax Incentive changes within the 2018-19 Federal Budget released yesterday, 8 May 2018. The changes take on board some recommendations from ISA’s previous review of the programme, along with some of the government’s own savings and integrity measures. The R&D Tax Offset rate will change, commencing for years on or after 1 July 2018. For companies claiming the refundable offset with […]
Categories
- ATO Guidance and Materials
- AusIndustry Guidance and Materials
- Case Law
- For Accountants
- General Information
- Government Policy and Treasury
- Industry Specific Issues
- Interpretative Decisions
- Legislation and Parliamentary Matters
- R&D Tax Credit
- R&D Tax Funding Strategies
- R&D Tax Loans
- Tax Determinations
Archives
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- September 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- May 2013
- April 2013
- March 2013
- September 2012
- August 2012
- June 2012
Quick Contact
News & Research
News & Research
News & ResearchCBA Settlement of Disputed Claims for Software R&D Activities
CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute re: the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: […]
Australia’s Attractiveness for Clinical Trials
To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to […]
